Editas Medicine - EDIT Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last twelve months. There are currently 2 sell ratings, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" EDIT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares.
View EDIT analyst ratings or view top-rated stocks.

9 Wall Street analysts have issued 1-year price objectives for Editas Medicine's shares. Their EDIT share price forecasts range from $8.00 to $60.00. On average, they anticipate the company's share price to reach $24.78 in the next year. This suggests a possible upside of 94.6% from the stock's current price.
View analysts price targets for EDIT or view top-rated stocks among Wall Street analysts.

Editas Medicine's stock was trading at $26.55 at the start of the year. Since then, EDIT shares have decreased by 52.1% and is now trading at $12.73.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our EDIT earnings forecast.

Editas Medicine, Inc. (NASDAQ:EDIT) posted its earnings results on Wednesday, August, 3rd. The company reported ($0.78) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.06. The business earned $6.36 million during the quarter, compared to analysts' expectations of $4.29 million. Editas Medicine had a negative net margin of 580.16% and a negative trailing twelve-month return on equity of 34.83%. Editas Medicine's quarterly revenue was up 1578.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.81) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

(EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EDIT stock can currently be purchased for approximately $12.73.

Editas Medicine (NASDAQ:EDIT) has a market capitalization of $875.06 million and generates $25.54 million in revenue each year. The company earns $-192,500,000.00 in net income (profit) each year or ($2.70) on an earnings per share basis.

The company employs 264 workers across the globe.

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The official website for the company is www.editasmedicine.com. The company can be reached via phone at (617) 401-9000 or via email at mark.mullikin@editasmed.com.